产品
编 号：F749246
产品类型
规格
价格
是否有货
1mg
询价
询价
结构图
CAS No: 2135939-52-3
产品详情
生物活性：
Inbakicept is a dimeric human IL-15 receptor alpha (IL-15 Ra) sushi domain/human IgG1 Fc fusion protein and is an IL-15 superagonist complex. Inbakicept is able to form complex N-803 (Nogapendekin alfa inbakicept) with the IL-15 antibody Nogapendekin alfa in a 1:2 ratio. N-803 mimics the function of IL-15 and amplifies anti-CD20 mAb-mediated NK cell responses and antibody-dependent cellular cytotoxicity (ADCC). N-803 also increases degranulation and IFNγ production in cells.
体内研究：
Inbakicept (0.2 mg/kg；静脉注射；每周两次，持续 2 周) 在小鼠模型中增强利妥昔单抗对致死性 Daudi 淋巴瘤攻击的保护作用。Animal Model:SCID mice with Daudi models
Dosage:0.02 mg/kg, 0.05 mg/kg, 0.1 mg/kg, and 0.2 mg/kg
Administration:Intravenous injection; twice weekly, for 2 weeks
Result:Enhanced rituximab-directed control of Raji lymphoma challenge.
体外研究：
Inbakicept (0.01-1 nM；20 小时) 增强人 NK 细胞的细胞毒性并增加细胞毒性效应分子的表达。
Inbakicept is a dimeric human IL-15 receptor alpha (IL-15 Ra) sushi domain/human IgG1 Fc fusion protein and is an IL-15 superagonist complex. Inbakicept is able to form complex N-803 (Nogapendekin alfa inbakicept) with the IL-15 antibody Nogapendekin alfa in a 1:2 ratio. N-803 mimics the function of IL-15 and amplifies anti-CD20 mAb-mediated NK cell responses and antibody-dependent cellular cytotoxicity (ADCC). N-803 also increases degranulation and IFNγ production in cells.
体内研究：
Inbakicept (0.2 mg/kg；静脉注射；每周两次，持续 2 周) 在小鼠模型中增强利妥昔单抗对致死性 Daudi 淋巴瘤攻击的保护作用。Animal Model:SCID mice with Daudi models
Dosage:0.02 mg/kg, 0.05 mg/kg, 0.1 mg/kg, and 0.2 mg/kg
Administration:Intravenous injection; twice weekly, for 2 weeks
Result:Enhanced rituximab-directed control of Raji lymphoma challenge.
体外研究：
Inbakicept (0.01-1 nM；20 小时) 增强人 NK 细胞的细胞毒性并增加细胞毒性效应分子的表达。
产品资料
Copyright©2015-2024 沪ICP备2022026524号-1
沪公网安备